Intervention Review

You have free access to this content

Intranasal steroids for acute sinusitis

  1. Anca Zalmanovici Trestioreanu1,*,
  2. John Yaphe2

Editorial Group: Cochrane Acute Respiratory Infections Group

Published Online: 2 DEC 2013

Assessed as up-to-date: 22 MAY 2013

DOI: 10.1002/14651858.CD005149.pub4


How to Cite

Zalmanovici Trestioreanu A, Yaphe J. Intranasal steroids for acute sinusitis. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD005149. DOI: 10.1002/14651858.CD005149.pub4.

Author Information

  1. 1

    Beilinson Campus, Rabin Medical Center, Department of Family Medicine, Petah Tikva, Israel

  2. 2

    University of Minho, School of Health Science, Braga, Portugal

*Anca Zalmanovici Trestioreanu, Department of Family Medicine, Beilinson Campus, Rabin Medical Center, 39 Jabotinski Street, Petah Tikva, 49100, Israel. anca_z@hotmail.com.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 2 DEC 2013

SEARCH

[Figure 1]
Figure 1. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 2]
Figure 2. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 1 Proportion of participants with resolution of symptoms or improved (MFNS 400 µg daily).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 2 Proportion of participants with resolution of symptoms or improved (MFNS 200 µg daily).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 3 Proportion of participants with resolution of symptoms or improved (combined MFNS 200, 400 and 800 µg daily).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 4 Number of participants that dropped out from the study (MFNS 400 µg daily).
[Analysis 1.5]
Analysis 1.5. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 5 Number of participants that dropped out from the study (MFNS 200 µg daily).
[Analysis 1.6]
Analysis 1.6. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 6 Number of participants that dropped out from the study (combined MFNS 200, 400 and 800 µg daily).
[Analysis 1.7]
Analysis 1.7. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 7 Relapse (combined 200 and 400 µg daily).